ANL vs. TVTX, KALV, ATXS, YMAB, TRDA, CRBP, ESPR, VERV, APLT, and OLMA
Should you be buying Adlai Nortye stock or one of its competitors? The main competitors of Adlai Nortye include Travere Therapeutics (TVTX), KalVista Pharmaceuticals (KALV), Astria Therapeutics (ATXS), Y-mAbs Therapeutics (YMAB), Entrada Therapeutics (TRDA), Corbus Pharmaceuticals (CRBP), Esperion Therapeutics (ESPR), Verve Therapeutics (VERV), Applied Therapeutics (APLT), and Olema Pharmaceuticals (OLMA). These companies are all part of the "pharmaceutical preparations" industry.
Adlai Nortye (NASDAQ:ANL) and Travere Therapeutics (NASDAQ:TVTX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings, valuation and community ranking.
Adlai Nortye has a net margin of 0.00% compared to Travere Therapeutics' net margin of -87.94%. Adlai Nortye's return on equity of 0.00% beat Travere Therapeutics' return on equity.
In the previous week, Travere Therapeutics had 5 more articles in the media than Adlai Nortye. MarketBeat recorded 5 mentions for Travere Therapeutics and 0 mentions for Adlai Nortye. Adlai Nortye's average media sentiment score of 0.47 beat Travere Therapeutics' score of 0.11 indicating that Adlai Nortye is being referred to more favorably in the media.
Adlai Nortye has higher earnings, but lower revenue than Travere Therapeutics.
Travere Therapeutics received 49 more outperform votes than Adlai Nortye when rated by MarketBeat users. However, 100.00% of users gave Adlai Nortye an outperform vote while only 48.62% of users gave Travere Therapeutics an outperform vote.
Adlai Nortye presently has a consensus price target of $30.00, indicating a potential upside of 126.42%. Travere Therapeutics has a consensus price target of $16.69, indicating a potential upside of 175.45%. Given Travere Therapeutics' higher probable upside, analysts clearly believe Travere Therapeutics is more favorable than Adlai Nortye.
35.2% of Adlai Nortye shares are owned by institutional investors. 3.8% of Travere Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Summary
Adlai Nortye beats Travere Therapeutics on 7 of the 13 factors compared between the two stocks.
Get Adlai Nortye News Delivered to You Automatically
Sign up to receive the latest news and ratings for ANL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ANL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Adlai Nortye Competitors List
Related Companies and Tools
